연구동향 분석

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations

박세훈 김범석 김세현 김기환 김유정 김진수 김태민 이세훈 김동완 이종석 허대석 2015년

논문상세정보
인용/피인용
' Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • epidermalgrowthfactorreceptor
  • non-small-cell lung carcinoma
  • pemetrexed
  • platinum
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,347 0

0.0%

' Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations' 의 참고문헌

  • Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
    Keam B Int J Clin Oncol 19 : 594 ~ 600 [2014]
  • Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
    Keam B Int J Clin Oncol 19 594-600 [2014]
  • Randomized phase III trial of singleagent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2
    Zukin M J Clin Oncol 31 : 2849 ~ 2853 [2013]
  • Randomized phase III trial of singleagent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2
    Zukin M J Clin Oncol 31 2849-2853 [2013]
  • Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung
    Nakagawa T Lung Cancer 35 : 165 ~ 170 [2002]
  • Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung
    Nakagawa T Lung Cancer 35 165-170 [2002]
  • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer
    Scagliotti GV J Clin Oncol 26 : 3543 ~ 3551 [2008]
  • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer
    Scagliotti GV J Clin Oncol 26 3543-3551 [2008]
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer EA Eur J Cancer 45 : 228 ~ 247 [2009]
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer EA Eur J Cancer 45 228-247 [2009]
  • NCCN clinical practice guidelines in oncology: non-small cell lung cancer. ver. 4.2014
    National Comprehensive Cancer Network National Comprehensive Cancer Network [2014]
  • Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer : data from the randomized phase III INTEREST trial
    Douillard JY J Clin Oncol 28 : 744 ~ 752 [2010]
  • Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer : data from the randomized phase III INTEREST trial
    Douillard JY J Clin Oncol 28 744-752 [2010]
  • Molecular changes of epidermal growth factor receptor(EGFR)and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung
    Kim YT Lung Cancer 59 : 111 ~ 118 [2008]
  • Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung
    Kim YT Lung Cancer 59 111-118 [2008]
  • Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy
    Huang CL Int J Oncol 17 : 47 ~ 54 [2000]
  • Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy
    Huang CL Int J Oncol 17 47-54 [2000]
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial
    Mitsudomi T Lancet Oncol 11 : 121 ~ 128 [2010]
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial
    Mitsudomi T Lancet Oncol 11 121-128 [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 : 2380 ~ 2388 [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 2380-2388 [2010]
  • First-SIGNAL : first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
    Han JY J Clin Oncol 30 : 1122 ~ 1128 [2012]
  • First-SIGNAL : first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
    Han JY J Clin Oncol 30 1122-1128 [2012]
  • Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial
    Rosell R Lancet Oncol 13 : 239 ~ 246 [2012]
  • Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial
    Rosell R Lancet Oncol 13 239-246 [2012]
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study
    Zhou C Lancet Oncol 12 : 735 ~ 742 [2011]
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study
    Zhou C Lancet Oncol 12 735-742 [2011]
  • EGFR testing in lung cancer is ready for prime time
    Hirsch FR Lancet Oncol 10 : 432 ~ 433 [2009]
  • EGFR testing in lung cancer is ready for prime time
    Hirsch FR Lancet Oncol 10 432-433 [2009]
  • EGFR mutations as a predictive marker of cytotoxic chemotherapy
    Park JH Lung Cancer 77 : 433 ~ 437 [2012]
  • EGFR mutations as a predictive marker of cytotoxic chemotherapy
    Park JH Lung Cancer 77 433-437 [2012]
  • Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer
    Schiller JH N Engl J Med 346 92-98 [2002]
  • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Schiller JH N Engl J Med 346 : 92 ~ 98 [2002]
  • Clinical cancer advances 2012 : annual report on progress against cancer from the american society of clinical oncology
    Roth BJ J Clin Oncol 31 : 131 ~ 161 [2013]
  • Clinical cancer advances 2012 : annual report on progress against cancer from the american society of clinical oncology
    Roth BJ J Clin Oncol 31 131-161 [2013]
  • Chemotherapy for non-small-cell lung cancer. Part 1: early-stage disease
    Novello S Oncology(Williston Park) 17 : 357 ~ 364 [2003]
  • Chemotherapy for non-small-cell lung cancer. Part 1: early-stage disease
    Novello S Oncology(Williston Park) 17 357-364 [2003]
  • Chemotherapy for elderly patients with advanced non-small-cell lung cancer : the Multicenter Italian Lung Cancer in the Elderly Study(MILES)phase III randomized trial
    Gridelli C J Natl Cancer Inst 95 : 362 ~ 372 [2003]
  • Chemotherapy for elderly patients with advanced non-small-cell lung cancer : the Multicenter Italian Lung Cancer in the Elderly Study(MILES)phase III randomized trial
    Gridelli C J Natl Cancer Inst 95 362-372 [2003]
  • Cancer statistics, 2012
    Siegel R CA Cancer J Clin 62 : 10 ~ 29 [2012]
  • Cancer statistics, 2012
    Siegel R CA Cancer J Clin 62 10-29 [2012]
  • American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    Azzoli CG J Clin Oncol 27 : 6251 ~ 6266 [2009]
  • American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    Azzoli CG J Clin Oncol 27 6251-6266 [2009]
  • Activating mutationsin the epidermal growth factor receptor underlying responsivenessof non-small-cell lung cancer to gefitinib
    Lynch TJ. N Engl J Med 350 : 2129 ~ 2139 [2004]
  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib
    Lynch TJ N Engl J Med 350 2129-2139 [2004]
  • A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2
    Lilenbaum R . J Clin Oncol 30 (Suppl) : 7506 ~ [2012]
  • A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2
    Lilenbaum R J Clin Oncol 30 Suppl 7506- [2012]